These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32660816)

  • 1. Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations.
    Kwon HY; Kim J
    Health Policy; 2020 Sep; 124(9):965-970. PubMed ID: 32660816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Pricing in South Korea.
    Kwon HY; Godman B
    Appl Health Econ Health Policy; 2017 Aug; 15(4):447-453. PubMed ID: 28138932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
    Berkemeier F; Whaley C; Robinson JC
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Price negotiation and pricing of anticancer drugs in China: An observational study.
    Zhou J; Lan T; Lu H; Pan J
    PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations.
    DiStefano MJ; Levy JF; Odouard IC; Anderson GF
    Value Health; 2023 Nov; 26(11):1618-1624. PubMed ID: 37689264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
    Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
    Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
    Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
    Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
    Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
    [No Abstract]   [Full Text] [Related]  

  • 9. Progress on drug pricing negotiations in China.
    Tang M; Song P; He J
    Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy.
    Rossini EE; Galeone C; Lucchetti C; Jommi C
    Pharmacoecon Open; 2024 Mar; 8(2):251-261. PubMed ID: 38228997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea.
    Heo JH; Rascati KL; Lee EK
    Value Health Reg Issues; 2017 May; 12():7-19. PubMed ID: 28648319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.
    Wettstein DJ; Boes S
    BMC Health Serv Res; 2021 Mar; 21(1):234. PubMed ID: 33726735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
    Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
    Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence.
    Wettstein DJ; Boes S
    Health Policy; 2022 Feb; 126(2):112-121. PubMed ID: 35000803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Access to medicines and South-South cooperation: a case study on joint drug price negotiations in South America].
    Oliveira BNL; Oliveira MA
    Cad Saude Publica; 2021; 37(10):e00170920. PubMed ID: 34730691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of early phase price agreements on prices of orphan drugs.
    Nuijten M; Van Wilder P
    BMC Health Serv Res; 2021 Mar; 21(1):222. PubMed ID: 33711994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Health Technology Assessment in Drug Policies: Korea.
    Bae EY
    Value Health Reg Issues; 2019 May; 18():24-29. PubMed ID: 30419447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
    Huang C; Ung COL; Wushouer H; Bai L; Huang T; Li X; Guan X; Shi L
    Health Res Policy Syst; 2022 Jan; 20(1):3. PubMed ID: 34980159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
    Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
    Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
    Robinson JC; Panteli D; Ex P
    Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.